Investigating biomarkers to improve outcomes in early psychosis treatment
5/5 - Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
This study is looking at how certain biological signs and health details can help predict how young adults with early psychosis will do over time, so that doctors can create more personalized treatment plans to improve their recovery and overall well-being.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10880352 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific biological markers and clinical features can predict the outcomes of early psychosis in young adults. By analyzing data from patients receiving coordinated specialty care, the study aims to categorize individuals based on their unique biomarker profiles and track their progress over time. The goal is to enhance treatment planning by tailoring interventions to the predicted trajectories of each patient, ultimately improving recovery rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are young adults aged 18-35 who are experiencing early symptoms of psychosis, including those with bipolar disorder or schizophrenia.
Not a fit: Patients who are outside the age range of 18-35 or those who do not have a diagnosis of early psychosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for individuals experiencing early psychosis.
How similar studies have performed: Previous research has shown promise in using biomarker categorization to predict outcomes in psychosis, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Clementz, Brett a — University of Georgia
- Study coordinator: Clementz, Brett a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.